<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>BioHealth Investor &#187; Pfizer acquisitions</title>
	<atom:link href="http://biohealthinvestor.com/tag/pfizer-acquisitions/feed" rel="self" type="application/rss+xml" />
	<link>http://biohealthinvestor.com</link>
	<description>Biotech and Medical Business Information</description>
	<lastBuildDate>Sat, 31 Jul 2010 00:09:03 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.1</generator>
		<item>
		<title>Pfizer Tests Waters For Major Acquisitions (PFE, AMGN, WYE, GILD, BMY, LLY, SGP, CELG, GENZ, BIIB)</title>
		<link>http://biohealthinvestor.com/2009/01/pfizer-tests-waters-for-major-acquisitions-pfe-amgn-wye-gild-bmy-lly-sgp-celg-genz-biib-2.html</link>
		<comments>http://biohealthinvestor.com/2009/01/pfizer-tests-waters-for-major-acquisitions-pfe-amgn-wye-gild-bmy-lly-sgp-celg-genz-biib-2.html#comments</comments>
		<pubDate>Mon, 05 Jan 2009 14:14:28 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[General]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[amgn]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[drug mergers]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[pfizer]]></category>
		<category><![CDATA[Pfizer acquisitions]]></category>
		<category><![CDATA[Pfizer Buyout Targets]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[WYE]]></category>

		<guid isPermaLink="false">http://www.biohealthinvestor.com/?p=1577</guid>
		<description><![CDATA[It hasn&#8217;t taken long for the speculation machine to roll down Wall Street in 2009.  A report from the FT over the weekend shows that Pfizer Inc. (NYSE: PFE) is willing to acquire some large rivals.  We believe that this is a mere testing of the waters by the company now that its troubles have [...]]]></description>
			<content:encoded><![CDATA[<p>It hasn&#8217;t taken long for the speculation machine to roll down Wall Street in 2009.  A report from the FT over the weekend shows that Pfizer Inc. (NYSE: PFE) is willing to acquire some large rivals.  We believe that this is a mere testing of the waters by the company now that its troubles have been persistent, but we also gave a whole list of these stocks in pharma and biotech which we feel are large enough to make an impact at the company.  You can see <a href="http://www.247wallst.com/2009/01/is-pfizer-about.html">our full synopsis on this</a> at 24/7 Wall St. and here is the list of the names we included:</p>
<p>Stock (Ticker)                              MktCap<br />
Amgen Inc. (AMGN)                     $62.5B<br />
Wyeth (WYE)                                 $51.1B<br />
Gilead Sciences Inc. (GILD)          $47.5B<br />
Bristol-Myers Squibb Co. (BMY)   $47.3B<br />
Eli Lilly &amp; Co. (LLY)                      $46.1B<br />
Schering-Plough Corp. (SGP)       $28.2B<br />
Celgene Corporation (CELG)        $25.9B<br />
Genzyme Corp. (GENZ)                $18.4B<br />
Biogen Idec Inc. (BIIB)                  $14.1B</p>
<p>JON OGG</p>
<p>January 5, 2009</p>
]]></content:encoded>
			<wfw:commentRss>http://biohealthinvestor.com/2009/01/pfizer-tests-waters-for-major-acquisitions-pfe-amgn-wye-gild-bmy-lly-sgp-celg-genz-biib-2.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
